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ABSTRACT 
Contrast agents, such as iron oxide, enhance MR images by altering the relaxation times of tissues in which the 
agent is present. They can also be used to label targeted molecular imaging probes. Unfortunately, no molecular imaging 
probe is currently available on the clinical MRI market. A promising platform for MRI contrast agent development is 
nanotechnology, where superparamagnetic iron oxide nanoparticles (SPIONS) are tailored for MR contrast enhancement, 
and/or for molecular imaging. SPIONs can be produced using a range of methods and the choice of method will be 
influenced by the characteristics most important for a particular application. In addition, the ability to attach molecular 
markers to SPIONS heralds their application in molecular imaging.  
There are many reviews on SPION synthesis for MRI; however, these tend to be targeted to a chemistry audience. 
The development of MRI contrast agents attracts experienced researchers from many fields including some researchers 
with little knowledge of medical imaging or MRI. This situation presents medical radiation practitioners with 
opportunities for involvement, collaboration or leadership in research depending on their level of commitment and their 
ability to learn. Medical radiation practitioners already possess a large portion of the understanding, knowledge and 
skills necessary for involvement in MRI development and molecular imaging. Their expertise in imaging technology, 
patient care and radiation safety provides them with skills that are directly applicable to research on the development and 
application of SPIONs and MRI.  
   In this paper we argue that MRI SPIONs, currently limited to major research centres, will have widespread 
clinical use in the future. We believe that knowledge about this growing area of research provides an opportunity for 
medical radiation practitioners to enhance their specialised expertise to ensure best practice in a truly multi-disciplinary 
environment. This review outlines how and why SPIONs can be synthesised and examines their characteristics and 
limitations in the context of MR imaging. © 2010 Biomedical Imaging and Intervention Journal. All rights reserved. 
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INTRODUCTION 
Nanotechnology has evolved into a 
multidisciplinary field, revolutionising industries such as 
applied physics, mechanical, chemical, electrical and 
biological engineering, machine design, robotics, and 
medicine [1]. In medical imaging, the development of 
nanoparticles has attracted a phenomenal amount of 
research, particularly for applications in molecular 
imaging.  
The nano size (<100nm) of these particles enables 
conjugation with many molecular markers, which can 
interact at molecular and cellular levels, thereby offering 
an ever increasing range of disease targets for molecular 
imaging. 
Nanoparticles also have the potential to 
revolutionise conventional imaging techniques [2]. 
Conventional imaging modalities lack the combination 
of high sensitivity and high spatial resolution required 
for molecular imaging. MRI has high resolution, but 
lacks sensitivity to molecular signals, while high 
sensitivity nuclear medicine modalities such as single 
photon emission computed tomography (SPECT) and 
positron emission tomography (PET) provide superb 
sensitivity, at the cost of reduced spatial resolution [2-4]. 
The use of nanoparticles in modalities like MRI can 
greatly increase sensitivity, presenting the potential for 
high-resolution molecular imaging. MRI has high spatial 
resolution [2, 5], is non-invasive in nature, uses non-
ionising radiation, and offers multi-planar tomographic 
capabilities [2]. Nanoparticles can be engineered to have 
magnetic characteristics that can be detected by MRI at 
low concentrations, and at the same time contain ligands 
which target specific molecules [2]. 
Iron oxide nanoparticles have been widely 
researched for MRI, as they are mainly 
superparamagnetic. There are several types of iron oxide 
nanoparticles, namely maghemite, γ-Fe2O3, magnetite, 
Fe3O4, and haematite, α-Fe2O3, among which magnetite, 
Fe3O4, is very promising, because of its proven 
biocompatibility [1].  
For molecular imaging purposes, superparamagnetic 
iron oxide nanoparticles (SPIONS) need to be 
biocompatible, non-toxic and magnetic. They also need 
to bind to a range of drugs, proteins, enzymes, antibodies, 
or other molecular targets. 
There have been a number of approaches to the 
production of SPIONS for use as MRI contrast agents, 
and each method produces particles with different sizes 
and magnetisation parameters. The iron oxide 
nanoparticles can also be coated with a surface layer, 
usually of organic material, that provides an interface 
between the core and the surrounding environment [6]. 
This surface layer can be used to direct the particles to a 
target site. 
In this review, we summarise some of the chemical 
routes for the synthesis of SPIONS, such as classical 
synthesis, reactions in constrained environments, and 
high temperature reactions. It will also discuss some of 
the major methods for structural and physicochemical 
characterisation of the SPIONS, such as x-ray powdered 
diffraction (XRD), transmission electron microscopy 
(TEM), dynamic light scattering (DLS), nuclear 
magnetic resonance spectroscopy (NMR), and atomic 
absorption spectroscopy (AAS). 
SYNTHESIS OF IRON OXIDE NANOPARTICLES 
Nanoparticle design 
Nanoparticles, being the smallest building block, 
can essentially be synthesised to have any structure, and 
can comprise a core and/or monolayer(s). For example, 
some drug delivery applications use multiple polymer 
layers surrounding an organic core [7], while some 
imaging applications use a basic structure that 
incorporates an inorganic core surrounded by an organic 
monolayer. The main materials used for the cores include 
metals such as gold (Au), platinum (Pt), silver (Ag), 
cobalt (Co), semiconductors cadmium selenide (CdSe), 
lead selenide (PbSe), or hybrids CdSe/zinc selenide(ZnS) 
[8].  
Materials suitable for composing the organic 
monolayer can include; silica shells [12, 13], lipids [14-
17], polymers [18, 19] and amphiphilic ligands [3, 9-11]. 
This layer can also be augmented with non-specific 
ligands or DNA fragments, antibodies, proteins, and 
drugs. 
The choice of core and monolayer material is critical 
to the design of specialised contrast agents as each layer 
dictates a specific function. The composition of the core 
material dictates the primary physical and chemical 
properties of the nanoparticle, which in turn determine 
how it can be imaged. Iron particles, for example, are 
potentially very useful as MRI contrast agents because 
they are magnetic and behave as single magnetic 
domains when exposed to an external magnetic field. On 
the other hand, CdSe nanoparticles or ‘quantum dots’ can 
be used as optical probes for fluorescent imaging. 
The monolayer provides the interface between the 
core and the surrounding environment [6] and can serve 
two purposes. Firstly, to act as a barrier between the 
nanoparticle core and the environment, to protect and 
stabilise the core [6]. Some materials used for the core 
such as iron oxides, on their own, are not stable, and are 
readily oxidised, changing valuable properties of the 
nanoparticle. Secondly, the chemical nature of 
monolayers dictate the reactivity, solubility and 
interfacial interactions [6], and may also determine the 
biological handling, of the nanoparticle. Most of the 
inorganic cores are not soluble in aqueous environments, 
and monolayer designs serve to overcome this problem, 
particularly for in-vivo applications. The inorganic core, 
when used alone, does not have a specific target, 
however if the monolayer is a particular molecular 
precursor or is conjugated to a specific molecule, it can 
direct the particle to an area of interest. J Lodhia et al. Biomed Imaging Interv J 2010; 6(2):e12   3 
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Nanoparticle design for MRI 
As well as having a suitable iron core and 
monolayer, SPIONS, need to possess a range of other 
properties to ensure they are useful as MRI contrast 
agents. These are: 
●  uniform particle size [20, 21] 
●  a uniform and high superparamagnetic moment 
[2, 20, 21] 
●  high colloidal stability [2] 
●  low toxicity and high biocompatibility [2] 
The way SPIONs are produced has an influence on 
all of the above properties [2]. For MRI, these properties 
are important as they determine the overall effectiveness 
of the contrast agent. For example, an essential 
characteristic of an effective MRI contrast agent is a high 
saturation magnetisation value, (expressed in 
electromagnetic unit/gram, [emu/g]). Saturation 
magnetisation values are a measure of the magnetic 
moment, so higher values produce more magnetic 
susceptibility, and therefore stronger MRI signals [22]. 
Relaxation rates are a measure of the ability of a 
contrast agent to enhance the relaxation rate of water 
protons, i.e. increase the efficiency with which image 
contrast is produced [23]. SPIONS with high T2 values 
have faster relaxation with surrounding water protons, 
and therefore faster relaxation rates (1/T1 and 1/T2).  
Typically, magnetisation values for SPIONS range 
from 30-50emu/g, while higher values such as 90emu/g 
have been observed for bulk material [24, 25]. Factors 
contributing to the magnetisation value of SPIONS 
include; the size of the particles (with the highest emu/g 
to volume ratio occurring in the 6-20nm particle size 
range [26]), spacing between the nanoparticles (where 
coatings such as silica separate the magnetic domains, 
allowing each individual magnetite particle to act 
independently and thus enhancing the net magnetism per 
gram) and the crystalline structure of the iron oxide. It is 
therefore essential to use a method of SPION production 
that generates particles with one or more of the above 
characteristics. 
The overall size and size distribution of the SPIONS 
is an important consideration as it can affect the 
biocompatibility and biodistribution in-vivo. It is well 
known that particles above 50nm in diameter are 
eliminated by the reticulo-endothelial system (RES) so 
SPIONs greater than 50nm in diameter are limited to 
liver/spleen imaging. A range of synthesis methods have 
been developed to produce SPIONs with varying sizes 
and this relationship between size and biocompatibility 
will be discussed in the following section. 
Other properties, such as high colloidal stability and 
low toxicity, are important, because they increase the 
chances of translating developmental contrast agents into 
the clinical setting.  
The following sections will briefly discuss the basic 
method of SPION growth, and then discuss the different 
methods of SPION production and their respective 
properties for MRI. 
Nucleation and particle growth 
In making iron oxide nanoparticles for MRI, the 
particles need to be of uniform size. Uniform particles 
are usually prepared via homogeneous precipitation 
reactions [2], which involve two processes, nucleation 
and growth. This is because iron oxide nanoparticles are 
crystalline structures that are governed by the principles 
of crystal formation and growth. Generally, for 
precipitation to occur, there must be a saturated solution, 
in which addition of any excess solute will cause 
precipitation, and the formation of nanocrystals [8].  
For nucleation to occur, the solution must be 
supersaturated [2], leading to a short single burst of 
nucleation [27]. Supersaturation can be achieved by 
dissolving the solute at a high temperature, or by adding 
reactants to produce supersaturation [28]. After the short 
burst in nucleation, the concentration drops and 
nucleation stops. The nuclei then grow, by diffusion of 
solutes from the solution onto the nuclear surfaces, until 
an equilibrium concentration is achieved. 
In order to achieve monodisperse particles, the two 
phases of nucleation and growth need to be separated [8, 
20, 27, 29]. There are many different mechanisms which 
can explain this process, however we refer the reader to 
LaMer and Dinegar [30], who proposed the classical 
theory method of the formation of sulphur colloids, Den 
Ouden and Thompson who explained ‘Ostwald ripening 
growth’ [31, 32] and other mechanisms proposed by 
Morales et al. [33], and Ocana et al. [34]. 
Size control is ultimately achieved by artificially 
separating nucleation and growth. This would occur 
before the solution reaches critical supersaturation, or by 
the end of nucleation [20]. A wide variety of factors have 
been adjusted in many ways to promote separation of the 
two processes to control size, magnetic characteristics, or 
surface properties. Some of the factors have contributed 
to the development of new synthesis methods, and some 
have just improved classical methods. A few of these 
factors will be discussed below. 
Methods of superparamagnetic iron oxide nanoparticle 
synthesis 
There are numerous methods of iron oxide 
nanoparticle synthesis for applications to MRI [20], for 
example; chemical precipitation, constrained 
environments and high temperature reactions. In keeping 
with the scope of this paper, only these selected methods 
will be discussed. 
Chemical precipitation 
The precipitation method is the simplest chemical 
pathway to obtain SPIONS [8, 20]. 
The SPIONS, either magnetite (Fe3O4), or 
maghemite (γFe2O3), are prepared by co-precipitating a 
stoichiometric mixture of ferrous and ferric salts in an 
aqueous medium. The thermodynamics of the reaction 
require a ratio of 2:1 for Fe
2+/ Fe
3+, and a pH between 8 
and 14. The precipitated magnetite is black in colour. 
The overall reaction can be written as [1, 20]: J Lodhia et al. Biomed Imaging Interv J 2010; 6(2):e12   4 
    This page number is not 




- → Fe3O4 + 4H2O (1) 
The ions can become oxidised before precipitation, 
critically affecting the physical and chemical properties 
of the SPIONS. For iron oxide, or magnetite, oxidation 
usually means the formation of maghemite. The reaction 
must therefore be carried out under a nitrogen 
environment to eliminate oxidation. 
The transformation from magnetite to maghemite 
can pose a serious problem for the production of contrast 
agents. The two differ from each other in the spinel 
structure; one occupies positions in the octahedral and 
tetrahedral sites, and the other, maghemite, has cationic 
vacancies in the octahedral position. This crystal 
structure results in a different net spontaneous 
magnetisation (or emu/g) of the iron particles : at 300
oK, 
92 emu/g
-1 for magnetite, and 78 emu/g
-1 for maghemite 
[35].  
Most of the time it is difficult to separate magnetite 
from maghemite [36], given that their diffraction spectra 
are very similar [21]. Some synthesis methods suggest 
the presence of both magnetite and maghemite in the 
resulting preparations [37].  
In the co-precipitation process there are two main 
processes involved. The first is a short single burst of 
nucleation, followed by growth of the nuclei, as 
discussed in the previous section. The precipitation 
method provides an advantage because large quantities 
can be synthesised; however, problems arise from the 
wide particle size distribution. 
As mentioned above, size affects the magnetisation 
values as well as the biodistribution in-vivo. Factors that 
influence the biodistribution of a particle are important, 
as they also determine the possible MRI applications. To 
control the size, and size distribution, it is essential to 
adjust factors that determine the precipitation process. 
Numerous studies have been conducted adjusting factors 
such as pH, ionic strength, temperature, nature of salts, 
Fe
3+/Fe
2+ ratio, and addition of chelating agents, which 
improve the size and size distribution of the SPIONS 
produced.  
The Massart process describes the co-precipitation 
of ferrous and ferric chlorides, and hydroxides in an 
alkaline solution [38]. Parameters such as strength of the 
base (eg ammonia or NaOH), the pH value, added 
cations, and the Fe
3+/Fe
2+ ratio were evaluated, noting 
the effect on yield of the co-precipitation reaction and 
particle sizes. It was concluded that the size decreases as 
the pH, and/or Fe
3+/Fe
2+ ratio, increase, and as ionic 
strength in the medium increases.  
A comprehensive study on the ratio of Fe
2+/Fe
3+ was 
conducted by Jolivet et al. In 1992 [39] and 1994, 
illustrating the effects on size, morphology and magnetic 
characteristics. Small values of the Fe
2+/Fe
3+ ratio (<0.3) 
were known to form goethite. For ratios less than 0.5, but 
greater than 0.3, there were two phases, consisting of 
smaller (4nm) and larger nanoparticles. However, a ratio 
of 0.5 corresponded to magnetite stochiometry, and the 
particles were homogenous in size and composition.  
In 1999, Babes et al. [40] investigated different 
properties such as iron concentration, temperature and 
oxygen. It was highlighted that one of the most important 
parameters was the Fe
2+/Fe
3+ molar ratio. A high ratio 
produced larger particles, which is consistent with the 
literature [39, 41], suggesting that only ratios between 
0.4 and 0.6 produce monodisperse particles, suitable for 
use as contrast agents in MRI [20]. 
It is reported that the higher the pH and the ionic 
strength, the smaller the particle size and size distribution 
[41, 42]. Vayssières et al. [42] observed that for a higher 
pH and ionic strength, the particles were smaller due to 
the thermodynamics of the solution. At a lower pH and 
ionic strength, the particles continued to grow during the 
ageing phase associated with Ostwald ripening, thus 
forming larger particles. 
A recent study on the size of the SPIONS, and its 
effect on magnetisation and MR signal, was conducted 
by Young-wook Jun et al. [26]. The SPIONS were 
highly crystalline, monodisperse, and stoichiometric for 
magnetite, and ranged in size from 4nm to 12nm in 
diameter. The general trend suggested that as the 
nanoparticles increased in size, the T2-weighted MR 
signal intensity decreased, the particles therefore 
appearing hypointense on T2-weighted images.  
Apart from modulating the parameters of the 
reaction to achieve monodisperse particles, the addition, 
either in combination or individually, of chelating 
organic anions like citric acid [43, 44], amino acids, and 
dimercaptosuccinic acid (DMSA) [45], can also decrease 
the particle size by inhibiting the growth of the crystal 
nuclei. Polymer surface complexing agents, which form 
monolayers on the surface of the iron oxide, such as 
dextran [46], carbodextran, and silica [47] can also be 
added, instead of varying the reaction parameters.  
Some polymer complexing agents such as dextran, 
carbodextran and silica are commercially available, and 
are currently used in iron oxide-based MRI contrast 
agents. Examples are: silica-coated magnetite, AMI-121 
(Lumirem®- US) dextran-coated magnetite, 
Ferumoxides (Endorem® – Europe, Feridex® in the 
USA and Japan) and carboxydextran coated magnetite, 
Ferucarbotran (Resovist® – Europe and Japan). 
It should be noted that these agents can be used for 
any method of iron oxide production. The coatings often 
serve multiple purposes; they allow for water solubility 
[2], the attachment of various functional probes [2, 48], 
promote the formation of monodisperse particles [20, 45] 
and stabilise the magnetite core [6]. 
Although the co-precipitation method is the simplest 
and most efficient chemical pathway to obtain magnetic 
particles, it has disadvantages such as large particle size 
distribution, aggregation and poor crystallinity, resulting 
in low saturation magnetisation values. These 
disadvantages have led to the development of advanced 
methods of magnetite synthesis [1].  
Reactions in constrained environments 
Synthesis reactions in constrained environments 
have made use of lipid-based structures with amphiphiles 
[12, 49-53] and dendrimers [54]. J Lodhia et al. Biomed Imaging Interv J 2010; 6(2):e12   5 
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Lipid-based nanoparticles, or colloidal aggregates 
such as liposomes, micelles or microemulsions, are 
composed of lipids and/or other amphiphilic molecules. 
Amphiphiles (sometimes referred to as surfactants) are 
molecules with both hydrophilic (polar head) and 
hydrophobic (non-polar tail) parts that spontaneously 
assemble into aggregates in an aqueous solution [55]. 
Because of these properties, there are various geometries 
and sizes that can be formed due to unfavourable 
interactions between the hydrophobic tails and water [55], 
such as cylindrical, spherical, and bilayered.  
The hydrophobic tails can vary in length, affecting 
the ratio between hydrophilic and hydrophobic parts, and 
the hydrophilic heads can also vary in charge and size, 
affecting the overall curvature of the aggregate. Other 
factors, such as pH, temperature and concentration, can 
also affect the end-product. 
Mulder at al. [14] illustrate the various geometries 
that can be formed.  
In micelle-forming lipids, the hydrophobic chains 
are oriented toward the inside of the micelle, and the 
hydrophilic chains outward. Micelles for MR imaging 
contain a hydrophobic core, where the iron oxide core is 
stabilised by the surfactant, which limits particle 
nucleation and growth [8].  
The first magnetic nanoparticles formed in micelles 
were produced by oxidation of Fe
2+ salts [56]. The size 
of the magnetite particles were controlled by varying the 
temperature and the surfactant concentration [57]. 
Micelles give control to the particle size formed, 
however reverse micelles are of importance for 
applications to MRI. 
In reverse micelles, the hydrophilic head groups are 
towards the core of the micelle and the hydrophobic 
groups are directed outwards. Reverse micelles can 
solubilise relatively large amounts of water, which can 
be controlled, to make them suitable for the synthesis of 
nanoparticles. A diverse range of nanoparticles can be 
obtained by varying the nature and amount of surfactant, 
co-surfactant, and solvent. 
Reverse micelles are essentially formed by aqueous 
iron salt solutions, encapsulated by a surfactant that 
separates them from the surrounding organic solution. 
Publications have suggested that iron oxide nanoparticles 
synthesised via the reverse micelle process can be used 
for MRI applications [58]. For example Lee et al. [57], 
investigated an inexpensive, large-scale, and highly 
crystalline method of magnetite production. The 
synthesis was carried out at high temperatures whilst 
varying the relative proportion of iron salts, surfactant 
and solvents. It was suggested that the particle size could 
be controlled to produce monodisperse particles in one 
sample. 
Poly(ethylene glycol) (PEG) stabilised lipids can 
also be used for targeting and stabilising the iron oxide 
core [59]. The advantages of using PEG stabilised lipids 
are long blood circulation times, and water solubility, 
while the disadvantages are associated with difficult 
preparation methods, and excessive size separation 
processes [60]. 
Bi-layer forming lipids are used to create liposomes; 
they usually have a polar head group and two fatty acid 
chains. Iron oxides can be placed inside the liposomal 
lumen to create magnetoliposomes [61]. There are two 
types of magnetoliposomes; the first consists of water-
soluble iron oxide particles within an aqueous lumen 
[62]. The second contains iron oxide particles of 
approximately 15nm, covered with a lipid bi-layer [63]. 
The second type, developed by De Cuyper and 
Joniau [63], has been used in-vivo for MRI as a bone 
marrow contrast agent [15]. The magnetoliposomes are 
produced by first synthesising iron oxides in solution. 
The particles are then solubilised and stabilised by the 
addition of laurate, which acts as a surfactant. A solution 
with excess phospholipids is then added to the particles 
and undergoes dialysis for a number of days. The 
surfactant molecules on the iron oxide surface exchange 
with the phospholipid molecules which, over time, cause 
the formation of a lipid bi-layer on the iron oxides 
nanoparticles. Furthermore, molecules such as PEG can 
also be added to the lipid bi-layer, increasing the half life 
in blood [64] and therefore increasing the number of 
applications for MRI contrast. 
Dendrimers are a class of transfection agents that 
contain three components: core, branches and end-groups. 
When dendrimers are coated to iron oxides they are 
termed magnetodendrimers. Carboxylated 
polyamidoamine dendrimers have been used to coat and 
stabilise the iron oxide nanoparticles [54, 65]. More 
importantly, magnetodendrimers are well suited for the 
imaging of cell trafficking and migration using MRI [66-
68]. This is due to the charge on the polymer, which 
promotes a high non-specific affinity for cellular 
membranes, resulting in cellular internalisation [65, 67]. 
Generally, the oxidation of Fe(II) at an elevated 
temperature and pH, in the presence of dendrimers, 
results in the formation of highly stable and soluble 
SPIONS with dendrimers [54]. They have an 
approximate size of 20-30nm, and high T2 relaxivities 
[54]. Cells from different origins: mouse, rat or human, 
can then be easily labelled to the magnetodendrimers, by 
introducing the magnetodendrimers to the cell culture for 
1-2 days at low concentrations [66]. 
High temperature methods 
 Monodisperse particles with significant size control, 
and high crystallinity, can be achieved using high 
temperature methods. In this method, iron complexes are 
decomposed in the presence of surfactants and organic 
solvents. The high temperatures used in this method, and 
the nature of the solvent, result in the SPIONS having 
suitable size, and size distribution, with high crystallinity 
[69].  
There are many studies on the synthesis of SPIONS 
using the high temperature method, for example Sun and 
Zeng [70] prepared iron oxide nanoparticles of different 
sizes, 3nm to 20nm. In this reaction, iron(III) 
acetylacetonate was decomposed by heating at 265
oC in 
phenyl ether, alcohol, oleic acid, and oleylamine, to 
produce SPIONS 4nm in diameter. To make larger J Lodhia et al. Biomed Imaging Interv J 2010; 6(2):e12   6 
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particles, a seed-mediated growth was used, controlling 
the quantity of seeds added to obtain various sizes.  
Similarly, Hyeon et al. [71] formed an iron oleate 
complex from the decomposition of iron pentacarbonyl 
in the presence of octyl ether and oleic acid at 100
oC. 
After cooling to room temperature, (CH3)3NO was 
added, and then the SPIONS were obtained by heating, 
followed by refluxing. When the molar ratios of iron 
pentacarbonyl and oleic acid were changed from 1:2 to 
1:4, the particle size increased from 7nm to 11nm. 
In another study by Park et al. [72], iron salts were 
used instead of toxic organometallic compounds such as 
iron carbonyl. Iron salts are more suited for contrast 
agent research and applications in MRI because they are 
less toxic. An iron-oleic complex was formed using iron 
chlorides, (FeCl3·6H2O) and sodium oleate, which was 
slowly heated to 320
oC in 1-octadecene. The solution 
was aged at this temperature for 30 minutes, generating 
monodisperse iron oxide crystals. Various temperatures 
and solvents were also tried, which produced particles of 
different sizes and dispersity. It was concluded that 
monodisperse particles could be attributed to the 
separation of growth and nucleation phases, which 
occured at different temperatures; nucleation at 200-
240°C, and growth at 300°C. 
Monolayers for superparamagnetic iron oxide 
nanoparticles 
On their own, iron oxides are not very stable, and 
are not soluble in water. Stabilisation of SPIONS is 
essential to prevent against aggregation and oxidisation. 
Furthermore, for use as MRI contrast agents in-vivo, the 
SPIONS need to be soluble in water and be easily 
conjugated to molecular and cellular markers.  
As discussed briefly in the previous sections, there 
are numerous ways for SPIONS to achieve water 
solubility and stability. Some of these methods include 
coating with carboxylates (such as citric acid), inorganic 
materials such as silica, and polymers such as dextran 
and PEG. These compounds protect the iron core, and 
also provide an avenue for conjugation of molecular 
precursors, therefore providing a biocompatible 
functional component for the SPIONS. 
Carboxylates 
The surface of the magnetite nanoparticles can be 
stabilised in an aqueous dispersion by the absorption of 
citric acid [72]. This process, as described in Sahoo et al. 
[45], occurs by the citric acid being coordinated via one 
or two of the carboxylate functionalities, depending on 
steric necessity, and the curvature of the surface. As a 
result, at least one carboxylic acid group is exposed to 
the solvent, and this group is responsible for making the 
surface charged and hydrophilic. The presence of the 
terminal carboxylic group provides an avenue to 
extended bond formation with fluorescent dyes, proteins, 
hormone linkers, and other molecules, so that specific 
targeting within biological systems can be facilitated. 
Molecules such as DMSA can also be used to 
stabilise the SPIONS, achieve water solubility and allow 
conjugation of molecular precursors [73]. DMSA has 
successfully been used as a monolayer [74], where the 
DMSA is introduced to the SPIONS, in excess, through 
simple mixing. The DMSA binds to the magnetite 
surface through its carboxylate bonding, and the 
intermolecular disulfide cross-linking between surface-
bound DMSA ligands strengthens the stability. The 
remaining free carboxylic acid and thiol groups make the 
SPIONS hydrophilic, and can be used for further 
conjugation of target-specific antibodies. 
Silica 
Iron oxide nanoparticles can also be coated with 
silica [74]. Silica is an inert molecule that coats the 
surface of the iron oxide nanoparticle, and, as a result, 
prevents aggregation of the SPIONS, and provides 
stability [75]. This is achieved by two processes: 
(1) sheltering of the magnetic dipole interaction by the 
silica shell; and (2) charging the magnetic nanoparticles, 
as silica is negatively charged [47]. These two features 
are essential, particularly for applications in MRI, as 
aggregation of the magnetite particles can reduce or 
diminish their ability to be superparamagnetic [76].  
There are two widely used methods to produce 
silica-coated iron oxide nanoparticles. The first method 
is based on the Stober process [76], which comprises the 
hydrolysis and condensation of a sol-gel precursor such 
as tetraethyl orthosilicate (TEOS). There have been 
numerous studies conducted on the formation of iron 
oxides coated with silica using the Stober process [46, 
77].  
The second most common method of generating 
iron oxide-coated silica nanoparticles is via the 
microemulsion process, where reverse micelles are used 
to confine and control the silica coating. In this method, 
non-ionic surfactants are used to form inverse 
microemulsions for preparation or suspension of 
magnetic nanoparticles [78]. The silica is formed around 
the magnetic nanoparticles by hydrolysis and 
condensation of TEOS [79]. 
Dextran 
Dextran is a polysaccharide polymer that is 
composed of α-D-glucopyranosyl units and can vary in 
length (1000 to 2,000,000 Da) and branching. Dextran 
offers a suitable monolayer for SPIONS because of its 
biocompatibility [80]. The formation of iron oxide 
coated by dextran was first documented by Molday and 
Mackenzie [80]. In this study, dextran 40 000 was coated 
to the iron oxide nanoparticles by reacting a mixture of 
ferrous chloride and ferric chloride with the dextran 
polymers, under alkaline conditions.  
Other studies have looked at smaller dextran 
coatings such as dextran 10 000 [21, 81, 82]. Reducing 
the size of dextran has an effect on the formation and 
stability of the dextran-coated iron oxide nanoparticles 
[83, 84]. Paul et al. [85] describe that the smaller dextran J Lodhia et al. Biomed Imaging Interv J 2010; 6(2):e12   7 
    This page number is not 
    for citation purposes 
has significant effects on particle size, coating stability, 
and magnetic properties. It was concluded that SPIONS 
coated with a reduced dextran were more stable than 
those coated with a larger molecular weight dextran. 
Higher molecular weight dextran produced larger 
particles, and only the 10,000 Da dextran gave a particle 
with high magnetic properties. 
Characterisation of superparamagnetic iron oxide 
nanoparticles 
There is a wide variety of analysis tools to 
characterise SPIONS. It is important to define the exact 
characteristics of SPIONS, as these characteristics can 
influence the application of SPIONS in MRI.  
For any biological application, a range of tests such 
as biocompatibility, toxicity and efficacy, needs to be 
considered. However, within the scope of this paper, and 
for preliminary development of SPIONS in MRI, the 
most general properties that need to be analysed are the 
physical (size, shape, chemical phases) and magnetic 
(MR properties, magnetic saturation values (emu/g)) 
properties. 
Physical properties 
When analysing the size of the SPIONS, we are in 
fact measuring a range of dimensions. This includes 
different parts of the nanoparticle: size of the iron oxide 
core, size of the monolayer e.g. silica or DMSA, size of 
the iron oxide core and monolayer, e.g. silica or DMSA, 
combined. It also includes the size range of the particles 
present in the sample. 
The size of the iron oxide core can be determined by 
transmission electron microscopy (TEM) [83-85]. TEM 
gives the total particle size, core and monolayer, and also 
provides details on the size distribution and the shape of 
the SPIONS. There are two different types of TEM; low 
resolution and high resolution. With the high resolution 
TEM, the atomic arrangement of the SPIONS can be 
deduced. It also allows better characterisation, or 
separation, between the core and monolayer. The lattice 
arrangement and the surface atomic arrangement of the 
crystals can also be studied, by the use of diffraction 
patterns.  
Generally for TEM, a small portion of the sample is 
placed on a coated copper grid and then imaged. 
Although it provides precise direct information about 
size, size distribution and shape of the particles, it has 
several disadvantages such as operator bias, a risk of 
change in particle properties as the sample dries and 
contrasting of the sample [21]. 
Dynamic light scattering (DLS) is also a useful 
technique in particle size characterisation, and holds 
some advantages over TEM. DLS can obtain information 
about the size and size distribution in solutions generally 
at a lower cost and with less time. In DLS, the 
distribution of diffusion coefficients are calculated which 
are transformed into measurements of the hydrodynamic 
or total diameter of the particles [21, 86]. Like all 
modalities, DLS also has disadvantages such as 
contamination by dust or small amounts of aggregates in 
the sample; these can create misleading results [21]. 
X-ray powdered diffraction (XRD) can also be used 
to estimate the size of the particles, and the crystalline 
structure. XRD gives a diffraction pattern of the sample, 
and this is compared to a reference peak or pattern. Line 
broadening from the XRD pattern is used to calculate the 
crystal sizes [87], using the Scherrer formula, and these 
results can indeed be compared to the TEM results. 
Mossbauer spectroscopy is another method that can 
be used to approximate the size of the SPIONS [87] to 
complement DLS and TEM results. A resonant 
absorption of nuclear gamma radiation, e.g. of the non-
radioactive 
57Fe isotopes, gives information on the 
magnetic coupling of the sample, the valence state of the 
iron ions, and also on the size of the core. 
Magnetic properties 
Measurements of the magnetisation as a function of 
the applied magnetic field allow the determination of 
magnetic properties: magnetic susceptibility, saturation 
magnetisation, and r1 and r2 relaxivities. 
A vibrating sample magnetometer (VSM) or 
Superconducting Quantum Interference Device (SQUID) 
magnetometer can be used to analyse the magnetic 
properties. Parameters such as magnetic moment and 
hysteresis loop measurements can be measured. The 
necessary equipment is scarce, and although these 
parameters are useful, for the requirements of MRI, other 
analytical tools can be used. 
Nuclear magnetic resonance spectroscopy (NMR) 
can be used to analyse properties such as the T1 and T2 
relaxivities. After analysing the iron concentrations (see 
below), the r1 and r2 relaxivities can be calculated by 
plotting the T1 and T2 over the iron concentration [88]. 
Alternatively, MRI can be used, using the same process 
for analysis. 
Iron concentration 
The iron concentration of the sample is generally 
measured using atomic absorption spectroscopy (AAS), 
or inductively coupled plasma mass spectrometry 
(ICPMS). 
AAS compares light absorbance of the unknown 
sample with light absorbance from known calibrated 
standards. It is relatively easy to use and well understood; 
however some limitations are that only one sample can 
be measured at a time and there can be interference with 
some elements. On the other hand, ICPMS is a form of 
mass spectrometry that is highly sensitive and can 
determine a range of metals and non-metals at very low 
concentrations. 
MRI with SPIONS: current status and future directions 
The previous sections discuss many studies that 
have researched and developed SPIONS. Some research 
has improved magnetic characteristics, while other 
studies have developed novel methods for reducing the 
size of the SPIONS, as well as producing monodisperse J Lodhia et al. Biomed Imaging Interv J 2010; 6(2):e12   8 
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particles. Despite research over many years, SPIONS as 
MRI contrast agents, particularly for molecular imaging, 
are still not available clinically. The problems in the 
translation of SPION research for MRI to the clinic lie 
primarily in particle size: larger particles limit 
applications; dosage: large amounts of SPIONS are 
needed to produce adequate contrast; and production: the 
ability to adapt synthesis methods to industrial levels of 
production.  
SPIONS that are larger than 50nm are eliminated by 
the RES, therefore they are mainly useful for liver/spleen 
imaging applications. Smaller SPIONS are also taken up 
by the RES; however, because of their smaller size, their 
blood circulation time is longer, providing greater 
opportunity for specific localisation. SPIONS produced 
commercially generally have had narrow applications 
and have been withdrawn from some markets due to low 
demand. An example is SHU-55A, Resovist. Resovist 
has an iron oxide core of 4.3nm and is coated with 
carbodextran to a total diameter of 60nm. Resovist also 
has excellent T2 relaxivities of 151.0 mmol
-1sec -
1, and 
was used only for liver/spleen imaging. Products like 
OMP (Abdoscan) and AMI-121 (Lumirem, Gastromark) 
have total diameters of approximately 300nm and are 
coated with polystyrene and silica. They are 
administered orally and used for gastro-intestinal 
contrast. Unfortunately the prices of these products are 
high, and they are only available on the European and 
US markets.  
Smaller-sized SPIONS such as AMI-227 (Sinerem, 
Combidex) and SHU-55C (Supravist an optimisation of 
Resovist, SHU-55a) are ultra-small iron oxide particles 
coated with dextran and carboxy-dextran respectively. 
Both products yielded a total diameter of approximately 
20nm.They have been proposed for applications in 
lymph node and bone marrow imaging, as well as the 
imaging of inflammatory processes. These products are 
not yet approved and are still undergoing development 
and/or clinical trials. Another product, NC100150 
(Clariscan) for perfusion/MR angiography was 
discontinued. The iron core was 5-7nm, and it was 
coated with PEG, having a total diameter of 20nm.  
There are other SPION contrast agents that are 
available at a pre-clinical imaging level. Monocrystalline 
iron oxide particles (MION) are used for angiography, 
lymphography, tumour detection, and infarction. 
Companies such as BioPhysics Assay Laboratory 
(BioPAL) Inc. provide products such as Molday ION and 
Table 1  Summary of SPION Contrast Agents 
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FerroTrack that can be used for molecular and cellular 
imaging at the pre-clinical level. See Table 1 for a 
summary of SPION contrast agents. 
For SPIONS to be used for more than one 
application, they need to be coated with a monolayer that 
can promote the attachment of molecular and cellular 
probes. An example is a study by Hilger et al. [88], in 
which iron oxide nanoparticles were coated with dextran, 
and then attached to anti-Her2/neu antibodies via the 
carboxyl groups on the dextran surface, for breast cancer 
imaging. Most of the SPIONS available or undergoing 
developments (see Table 1) have suitable surface 
coatings for molecular/cellular imaging; however, their 
clinical and/or proposed uses have been restricted to 
relatively narrow generic roles. 
Another drawback in the translation of contrast 
agent research to the clinic has been the large amount of 
iron needed to produce adequate contrast. The challenge 
is to develop highly magnetic particles that can produce 
the strong signal enhancement, allowing low doses of 
SPION to be administered without compromising the 
MR signal. 
Other problems are in translating the synthesis of 
SPIONS, easily made in the lab, to industrial processes 
able to produce large quantities on a consistent basis.  
With the wide range of SPIONS that are currently 
being developed for single MR applications there are 
possibilities that in the future these SPIONS will be 
available for use as MR contrast agents. As for molecular 
and cellular imaging with MRI, the current research sets 
a platform for the further development of SPIONS. If 
SPIONS as MR contrast agents for single applications 
can be utilised, then the next step in SPION development 
would be towards molecular imaging. Although 
molecular imaging with MRI will not likely replace 
nuclear medicine and PET, it may play a useful 
complementary role. The current decade has seen 
extensive progress in SPION design, utilisation and 
characteristics, and we expect that the future will see 
highly magnetic SPIONS available for molecular and 
cellular imaging in MRI. 
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